nach oben

Erschienen in:

2021 | OriginalPaper | Buchkapitel

49. Systemischer Lupus Erythematodes (SLE) (engl. Systemic lupus erythematosus)

verfasst von : Sibylle Winterhalter, F. Hiepe

Erschienen in: Entzündliche Augenerkrankungen

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

ICD-10-Code M32 Systemischer Lupus erythematodes, M32.1+ Systemischer Lupus erythematodes mit Beteiligung von Organen oder Organsystemen

Alexander T, Radbruch A, Hiepe F (2015) Pathogenesis of systemic lupus erythematosus. Z Rheumatol 74(3):183–190PubMedCrossRef

Andreoli L, Bertsias GK, Agmon-Levin N et al (2017) EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 76:476–485PubMedCrossRef

Arevalo JF, Lowder CY, Muci-Mendoza R (2002) Ocular manifestations of systemic lupus erythematosus. Curr Opin Ophthalmol 13:404–410PubMedCrossRef

Aringer M, Costenbader K, Daikh D et al (2019) 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritits Rheum 71(9):1400–1412CrossRef

Arnett FC (1987) The HLA system and the genetics of lupus erythematosus. In: Wallace DJ, Dubois EL (Hrsg) Dubois’ lupus erythematosus, 3. Aufl. Lea and Febiger, Philadelphia, S 161–184

Asherson RA, Merry P, Acheson JF et al (1989) Antiphospholipid antibodies: a risk factor for occlusive ocular vascular disease in SLE and primary antiphospholipid syndrome. Ann Rheum Dis 48:358–361PubMedPubMedCentralCrossRef

Baglivo E, Ribi C (2016) Systemic lupus erythematosus. In: Zierhut M (Hrsg) Intraocular inflammation. Springer-Verlag, Heidelberg, S 803–814. https://doi.org/10.1007/978-3-540-75387-2_68

Biesen R, Rose T, Hoyer BF et al (2016) Autoantibodies, complement and type I interferon as biomarkers for personalized medicine in SLE. Lupus 25(8):823–829PubMedCrossRef

Chugh S, Darvish-Kazem S, Lim W et al (2015) Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol 2(e):75–81CrossRef

Cobo-Ibáñez T, Loza-Santamaría E, Pego-Reigosa JM et al (2014) Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum 44:175–185PubMedCrossRef

Costedoat-Chalumeau N, Dunogué B, Leroux G et al (2015) A critical review of the effects of hydroxychloroquine and chloroquine on the eye. Clin Rev Allergy Immunol 49:317–326PubMedCrossRef

Couturier A, Giocanti-Aurégan A, Dupas B et al (2017) Update on recommendations for screening for hydroxychloroquine retinopathy. J Fr Ophtalmol 40(9):793–800PubMedCrossRef

D’Cruz DP, Khamashat MA, Hughes GR (2007) Systemic lupus erythematosus. Lancet 369:587–596PubMedCrossRef

Dammacco R (2018) Systemic lupus erythematosus and ocular involvement: an overview. Clin Exp Med 18(2):135–149PubMedCrossRef

Dammacco R, Procaccio P, Racanelli V et al (2018) Ocular involvement in systemic lupus erythematosus: the experience of two tertiary referral centers. Ocul Immunol Inflamm 26(8):1154–1165PubMedCrossRef

Davies JB, Rao PK (2008) Ocular manifestations of systemic lupus erythematosus. Curr Opin Ophthalmol 19:512–518PubMedCrossRef

Fanouriakis A, Kostopoulou M, Alunno A et al (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78(6):736–745PubMedCrossRef

Flechsig A, Rose T, Barkhudaraova F et al (2017) What is the clinical significance of anti-SM antibodies in systemic lupus erythematosus? A comparison with anti-dsDNA antibodies and C3. Clin Exp Rheumatol 35(4):598–606PubMed

Gomez Mendes LM, Cascino MD, Garg J et al (2018) Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol 13:1502–1509CrossRef

Graham EM, Spalton DJ, Barnard RO et al (1985) Cerebral and retinal vascular changes in systemic lupus erythematosus. Ophthalmology 92:444–448PubMedCrossRef

Grimson BS, Simons KB (1983) Orbital inflammation, myositis and systemic lupus erythematosus. Arch Opthalmol 101:736–738CrossRef

Gross AJ, Hochberg D, Rand WM et al (2005) EBV and systemic lupus erythematosus: a new perspective. J Immunol 174:6599–6607PubMedCrossRef

Hall S, Buettner H, Luthra HS (1984) Occlusive retinal vascular disease in systemic lupus erythematosus. J Rheumatol 11:846–850PubMed

Herold G (2002) Systemischer Lupus Erythematodes, Lupusnephritis. In: Herold G (Hrsg) Innere Medizin. Springer-Verlag, Köln, S 551–554

Hiepe F (2014) Where is lupus hidden? Presse Med 43(Pt 2):e143–e150PubMedCrossRef

Huey C, Jakobiec FA, Iwarmoto T et al (1983) Discoid lupus erythematosus of the eyelids. Ophthalmology 90:1389–1398PubMedCrossRef

Iaccarino L, Andreoli L, Bocci EB et al (2018) Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a lage, multicentric, nationwide study. J Autoimmun 86:1–8PubMedCrossRef

Jabs DA, Miller NR, Newman SA et al (1986) Optic neuropathy in systemic lupus erythematosus. Arch Ophthalmol 104:564–568PubMedCrossRef

Kasitanon N, Intaniwet T, Wangkaew S et al (2015) The clinically quiescent phase in early-diagnosed SLE patients: inception cohort study. Rheumatology 54:868–875PubMedCrossRef

Kim J-W, Kim YY, Lee H et al (2017) Risk of retinal toxicity in longterm users of hydroxychloroquine. J Rheumatol 44:1674–1679PubMedCrossRef

Klinkhoff AV, Beattie CW, Chalmers A (1986) Retinopathy in systemic lupus erythematosus: relationship to disease activity. Arthritis Rheum 29:1152–1156PubMedCrossRef

Kucukkomurcu E, Unal AU, Esen F et al (2018) Ocular posterior segment involvement in patients with antiphospholipid syndrome and systemic lupus erythematosus. Ocul Immunol Inflamm 17:1–6. https://doi.org/10.1080/09273948.2018.1552759CrossRef

Kuhn A, Bonsmann G, Anders HJ (2015) The diagnosis and treatment of systemic lupus erythematosus. Dtsch Arztebl Int 112:423–432PubMedPubMedCentral

Kuhn A, Aberer E, Bata-Csörgő Z et al (2017) S2k guideline for the treatment of cutaneous lupus erythematosus – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 31:389–404

Lanham JB, Barrie T, Kohner EM et al (1982) SLE retinopathy: evaluation by fluorescein angiography. Ann Rheum Dis 41:473–478PubMedPubMedCentralCrossRef

Mackensen F, Rosenbaum JT, Max R (2011) Augenbeteiligung bei systemischem Lupus erythematodes. In: Joussen AM (Hrsg) Retinale Gefäßerkrankungen. Springer, Heidelberg, S 351–356

Md Yusof MY, Shaw D, El-Sherbiny YM et al (2017) Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Ann Rheum Dis 76:1829–1836PubMedCrossRef

Melles RB, Marmor MF (2014) The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol 132:1453–1460PubMedCrossRef

Merrill JT, Neuwelt CM et al (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62(1):222–233PubMedPubMedCentralCrossRef

Miescher PA (1986) Treatment of systemic lupus erythematosus. Springer Semin Immunopathol 9:271–282PubMedCrossRef

Nguyen QD, Uy HS, Akpek EK et al (2000) Choroidopathy in systemic lupus erythematosus. Arch Ophthalmol 106:230–234

Olfat M, Silverman ED, Levy DM (2015) Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus. Lupus 24:966–972PubMedCrossRef

Ordi-Ros J, Sáez-Comet L, Pérez-Cones M et al (2017) Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomized clinical trial. Ann Rheum Dis 76:1575–1582PubMedCrossRef

Osio-Salido E, Manapat- Reyes H (2010) Epidemiology of systemic lupus erythemtosus in Asia. Lupus 19:1365–1373PubMedCrossRef

Petri M, Kim MY, Kalunian KC et al (2005) Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353:2250–2258CrossRef

Prabu A, Marshall T, Gordon C et al (2003) Use of patient age and anti-R/La antibody status to determine the probability of patients with systemic lupus erythematosus and sicca symptoms fulfilling criteria for secondary Sjögren’s syndrome. Rheumatology (Oxford) 42:189–191CrossRef

Rahman A, Isenberg DA (2008) Systemic lupus erythematosus. N Engl J Med 358:929–939PubMedCrossRef

Ramos-Casals M, Soto MJ et al (2009) Rituximab in systemic lupus erythematosus: a systematic review of of-label use in 188 cases. Lupus 18(9):767–776PubMedCrossRef

Sakthiaswary R, Suresh E (2014) Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. Lupus 23:225–235CrossRef

Sánchez- Guerrero J, Uribe AG, Jiménez- Santana L et al (2005) A trial of contraceptive methods in women with systemic luspus erythematosus. N Engl J Med 353:2539–2549PubMedCrossRef

Serris A, Amoura Z, Canouï-Poitrine F et al (2018) Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: a multicenter retrospective cohort study of 71 adults. Am J Hematol 93:424–429PubMedCrossRef

Silpa-archa S, Lee JJ, Foster CS (2016) Ocular manifestations in systemic lupus erythematosus. Br J Ophthalmol 100(1):135–141PubMedCrossRef

Sit JKK, Chan WKY (2018) Risk factors for damage in childhood-onset systemic lupus erythematosus in Asians: a case control study. Pediatr Rheumatol Online J 16(1):56. https://doi.org/10.1186/s12969-018-0271-8CrossRefPubMedPubMedCentral

Sitaula R, Shah DN, Singh D (2011) The spectrum of ocular involvement in systemic lupus erythamtosus in a tertiary eye care center in Nepal. Ocul Immunol Inflamm 19(6):422–425PubMedCrossRef

Staffort- Brady FJ, Urowitz MB, Gladmann DD et al (1988) Lupus retinopathy: patterns, associations and prognosis. Arthritis Rheum 31:1105–1110CrossRef

Steiman AJ, Urowitz MB, Ibañez D et al (2014) Prolonged clinical remission in patients with systemic lupus erythematosus. J Rheumatol 41:1808–1816PubMedCrossRef

Tan EM, Cohen AS et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25(11):1271–1277PubMedCrossRef

Taraborelli M, Leuenberger L, Lazzaroni MG et al (2016) The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus. Lupus 25:1365–1368PubMedCrossRef

Teoh SC, Yap EY, Eong KG (2001) Neuro-ophthalmological manifestations of systemic lupus erythematosus in Asian patients. Clin Exp Ophthalmol 29:213–216PubMedCrossRef

Tolba DA, El-Fayoumi DMS, Abdelaziz MS et al (2017) Fluorescein angiographic findings in patients with active systemic lupus erythematosus. Ocul Immunol Inflamm 25(6):884–890PubMedCrossRef

Tselios K, Gladman DD, Su J et al (2016) Mycophenolate mofetil in nonrenal manifestations of systemic lupus erythematosus: an observational cohort study. J Rheumatol 43:552–558PubMedCrossRef

Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ et al (2017) Remission and low disease activity status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American lupus cohort (GLADEL). Ann Rheum Dis 76:2071–2074PubMedCrossRef

Vital EM, Wittmann M, Edward S et al (2015) Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. Arthritis Rheum 67:1586–1591CrossRef

Walport MJ (2002) Complement and systemic lupus erythematosus. Arthritis Res 4(3):279–293CrossRef

Yehudai D, Shoenfeld Y, Toubi E (2007) Looking into the eyes of patients with antiphospholipid syndrome. Clinic Rev Allerg Immunol 32:192–197CrossRef

Titel: Systemischer Lupus Erythematodes (SLE) (engl. Systemic lupus erythematosus)
verfasst von: Sibylle Winterhalter
F. Hiepe
Verlag: Springer Berlin Heidelberg
Buch: Entzündliche Augenerkrankungen
Print ISBN: 978-3-662-60398-7

Electronic ISBN: 978-3-662-60399-4

Copyright-Jahr: 2021
DOI: https://doi.org/10.1007/978-3-662-60399-4_49

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

49. Systemischer Lupus Erythematodes (SLE) (engl. Systemic lupus erythematosus)

Zusammenfassung

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

So erreichen Sie eine bestmögliche Wundheilung der Kornea

Update Augenheilkunde